Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Acton

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Research Communications in Chemical Pathology and Pharmacology|April 1, 1988
Effects of D-5-hydroxytryptophan and D-DOPA on binding at serotonin and dopamine receptorsG Acton
Canadian Medical Association Journal|March 24, 2010
"Let's Ask the Doctor"G Acton
The Hospital|May 30, 2018
The Editor's Letter-BoxG Acton Davis
The Hospital|May 30, 2018
Freedom of Speech at St. Bartholomew's HospitalG Acton Davis
British Journal of Clinical Pharmacology|October 1, 1989
A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonistG Acton, C Broom
European Journal of Pharmacology|October 1, 1979
Evidence for an endogenous factor interfering with antagonist binding at the muscarinic cholinergic receptorG Acton, J W Dailey, S W Morris, et al.
Alimentary Pharmacology & Therapeutics|February 1, 1991
Effects of low-dose cimetidine on nocturnal acid secretion in healthy subjectsG Acton, C Broom, K Wareham, et al.
Nursing Outlook|July 1, 1991
Nurses' perspectives on a national health planH M Griffith, M Evans, B Irvin, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chainsMichael B Gravestock, David G Acton, Michael J Betts, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, David G Acton, Peter Ballard, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Research Communications in Chemical Pathology and Pharmacology|April 1, 1988
Effects of D-5-hydroxytryptophan and D-DOPA on binding at serotonin and dopamine receptorsG Acton
Canadian Medical Association Journal|March 24, 2010
"Let's Ask the Doctor"G Acton
The Hospital|May 30, 2018
The Editor's Letter-BoxG Acton Davis
The Hospital|May 30, 2018
Freedom of Speech at St. Bartholomew's HospitalG Acton Davis
British Journal of Clinical Pharmacology|October 1, 1989
A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonistG Acton, C Broom
European Journal of Pharmacology|October 1, 1979
Evidence for an endogenous factor interfering with antagonist binding at the muscarinic cholinergic receptorG Acton, J W Dailey, S W Morris, et al.
Alimentary Pharmacology & Therapeutics|February 1, 1991
Effects of low-dose cimetidine on nocturnal acid secretion in healthy subjectsG Acton, C Broom, K Wareham, et al.
Nursing Outlook|July 1, 1991
Nurses' perspectives on a national health planH M Griffith, M Evans, B Irvin, et al.
Bioorganic & Medicinal Chemistry Letters|November 19, 2003
New classes of antibacterial oxazolidinones with C-5, methylene O-linked heterocyclic side chainsMichael B Gravestock, David G Acton, Michael J Betts, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBernard Barlaam, David G Acton, Peter Ballard, et al.
Pageof 2